Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Nephrology | Family Medicine
Kidney Cancer Clinical Trials
A listing of Kidney Cancer medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
California
Duarte : City of Hope
A Prospective Investigation of the Use of the Fluorescence Imaging on the da Vinci Surgical System for Intraoperative Near Infrared Imaging of Renal Cortical Tumors
Duarte : City of Hope
Assessment of Bacteriomic Profiling and Other Biomarkers as Predictors of Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor (VEGF-TKI)-Induced Diarrhea in Patients with Metastatic Renal Cell Carcinoma (mRCC)
Duarte : City of Hope
Development of a Blood Test of Anti-IMP3 Autoantibody for the Detection of Renal Cell Carcinoma with Metastasis and Metastatic Potential
Duarte : City of Hope
ECOG E2810: Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Duarte : City of Hope
Phase I/II Study of BNC105P in Combination with Everolimus or Following Everolimus for Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Duarte : City of Hope
Phase I/II Study of Dalteparin, a Low Molecular Weight Heparin (LMWH), in Combination with Sunitinib (SU11248), an Oral, Selective Multi-Targeted Tyrosine Kinase Inhibitor, as First Line Treatment, in Patients with Metastatic Renal Cell Carcinoma
Duarte : City of Hope
PHII-121, NCI #9144: A Phase II Study of Bevacizumab Alone or in Combination with TRC105 for Advanced Renal Cell Cancer
Duarte : City of Hope
SWOG S0931: EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
Duarte : City of Hope
SWOG S1107: Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination with Erlotinib in Papillary Renal Cell Carcinoma
Colorado
Denver : The Urology Center of Colorado
Phase II, open-label study evaluating DN24-02 as adjuvant therapy in subjects with high risk HER2+ urothelial carcinoma.
Illinois
Elgin : Sherman Health
SWOG S0931 Phase III Randomized Study of Everolimus Versus Placebo in Patients With Renal Cell Carcinoma Who Have Undergone Nephrectomy or Partial Nephrectomy
Massachusetts
Boston : Beth Israel Deaconess Medical Center
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Boston : Dana-Farber Cancer Institute
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
New Jersey
New Brunswick : Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
Effects of Monoclonal Antibody GC1008 in Blood Samples From Patients With Unresectable Locally Advanced or Metastatic Kidney Cancer or Malignant Melanoma Treated on Clinical Trial NCI-06-C-0200
Tennessee
Nashville : Vanderbilt Univeristy Medical Center
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Texas
Houston : UT MD Anderson Cancer Center
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
Houston : UT MD Anderson Cancer Center
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
West Virginia
Morgantown : West Virginia University - Clinical Trials Research Unit
ECOG1808-A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features
